The functional role of xanthophylls in the primate retina

Carotenoids: Physical, Chemical, and Biological Functions and Properties

Volumn , Issue , 2009, Pages 257-282

  Schalch, Wolfgang ^a   Bone, Richard A ^b   Landrum, John T ^b  

^a DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLOR; DROPS; LIGHT; MAMMALS; PHOTOSYNTHESIS; PLANTS (BOTANY);

COLOR FILTERS; FISH SPECIES; NON-HUMAN PRIMATE; NON-PHOTOCHEMICAL QUENCHING; OIL DROPLETS; PHOTOSYNTHETIC ORGANISMS; PHOTOSYNTHETIC REACTION CENTER; VISUAL ACUITY;

PIGMENTS;

EID: 79954920364     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420052312     Document Type: Chapter

References (193)

1. Afzal, A. and M. Afzal (2008). Photoprotective carotenoids lutein and zeaxanthin: Their role in AMD. Curr. Nutr. Food Sci. 4(2): 127-134.
2. Aleman, T. S., J. L. Duncan et al. (2001). Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest. Ophthalmol. Vis. Sci. 42(8): 1873-1881.
3. Andreani, D. and U. Volpi (1956). Effect of helenien (adaptinol) on light sense in normal subjects and patients with retinitis pigmentosa (Italian). G. Ital. Oftal. 9: 565-573.
4. Arden, G. B. and F. M. Barker (1991). Canthaxanthin and the eye: A critical ocular and toxicological assessment. J. Toxicol. Cutaneous Ocular Toxicol. 10: 115-155.
5. AREDS Research Group (1999). The age-related eye disease study (AREDS): Design implications, AREDS Report No. 1. Contr. Clin. Trials 20: 573-600.
6. AREDS Research Group (2001). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β-carotene, and zinc for age-related macular degeneration and vision loss, AREDS Report No. 8. Arch. Ophthalmol. 119(10): 1417-1436.
7. AREDS Research Group, J. P. SanGiovanni et al. (2007). The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study, AREDS Report No. 22. Arch. Ophthalmol. 125(9): 1225-1232.
8. Asciano, F. and M. Bellizzi (1974). Light and colour sensitivity in malignant myopia before and after treatment with helenien and vitamin A (Italian). Annali Otal. 100: 191-202.
9. Azeredo, V. B. and N. M. Trugo (2008). Retinol, carotenoids, and tocopherols in the milk of lactating adolescents and relationships with plasma concentrations. Nutrition 24(2): 133-139.
10. Beatty, S., I. J. Murray et al. (2001). Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest. Ophthalmol. Vis. Sci. 42(2): 439-446.
11. Belloni, L. (1983). Contribution of Francesco Buzzi to the discovery of the macula lutea and the fovea centralis of the human eye (German). Gesnerus 40(1-2): 23-30.
12. Benzie, I. F., W. Y. Chung et al. (2006). Enhanced bioavailability of zeaxanthin in a milk-based formulation of wolfberry (Gou Qi Zi, Fructus barbarum L.). Br. J. Nutr. 96(1): 154-160.
13. Berendschot, T. T., R. A. Goldbohm et al. (2000). Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Invest. Ophthalmol. Vis. Sci. 41(11): 3322-3326.
14. Berendschot, T. T. and D. van Norren (2005). On the age dependency of the macular pigment optical density. Exp. Eye Res. 81(5): 602-609.
15. Berges, D., G. Schmitt et al. (1959). The effects of helenien and vitamin A on the primary sight process. III. A flame photometric determination of the potassium and sodium content of the retina (German). Z. Biol. 111: 220-227.
16. Bernstein, P. S., N. A. Balashov et al. (1997). Retinal tubulin binds macular carotenoids. Invest. Ophthalmol. Vis. Sci. 38: 167-175.
17. Bernstein, P. S., F. Khachik et al. (2001). Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp. Eye Res. 72(3): 215-223.
18. Bernstein, P. S., D. Y. Zhao et al. (2002). Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. Ophthalmology 109(10): 1780-1787.
19. Bhosale, P. and P. S. Bernstein (2005). Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation. Biochim. Biophys. Acta 1740(2): 116-121.
20. Bhosale, P. and P. S. Bernstein (2007). Vertebrate and invertebrate carotenoid-binding proteins. Arch. Biochem. Biophys. 458(2): 121-127.
21. Bhosale, P., A. J. Larson et al. (2004). Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) as a zeaxanthin-binding protein in the macula of the human eye. J. Biol. Chem. 279(47): 49447-49454.
22. Bone, R. A., J. T. Landrum et al. (1985). Preliminary identification of the human macular pigment. Vis. Res. 25(11): 1531-1535.
23. Bone, R. A., J. T. Landrum et al. (1988). Analysis of the macular pigment by HPLC: Retinal distribution and age study. Invest. Ophthalmol. Vis. Sci. 29(6): 843-849.
24. Bone, R. A., J. T. Landrum et al. (1993). Stereochemistry of the human macular carotenoids. Invest. Ophthalmol. Vis. Sci. 34: 2033-2040.
25. Bone, R. A., J. T. Landrum et al. (1997). Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp. Eye Res. 64: 211-218.
26. Bone, R. A., J. T. Landrum et al. (2001). Macular pigment in donor eyes with and without AMD: A case-control study. Invest. Ophthalmol. Vis. Sci. 42(1): 235-242.
27. Bone, R. A., J. T. Landrum et al. (2003). Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J. Nutr. 133(4): 992-998.
28. Bone, R. A., J. T. Landrum et al. (2007). Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. Nutr. Metab. (London) 4: 12.
29. Borel, P., M. Moussa et al. (2007). Human plasma levels of vitamin E and carotenoids are associated with genetic polymorphisms in genes involved in lipid metabolism. J. Nutr. 137(12): 2653-2659.
30. Boudreault, G., P. Cortin et al. (1893). Canthaxanthine retinopathy: 1. Clinical study in 51 consumers (French). Can. J. Ophthalmol. 18(7): 325-328.
31. Breithaupt, D. E., P. Weller et al. (2004). Comparison of plasma responses in human subjects after the ingestion of 3R,3R′-zeaxanthin dipalmitate from wolfberry (Lycium barbarum) and non-esterified 3R,3R′-zeaxanthin using chiral high-performance liquid chromatography. Br. J. Nutr. 91(5): 707-713.
32. Britton, G., S. Liaaen-Jensen et al. (2004). Handbook of Carotenoids. Birkhäuser AG, Basel, Switzerland.
33. Buzzi, F. (1782). Nuove sperienze fatte sull’ occhio umano dal sig. Fancesco Buzzi chirurgo oculista ed ajutante chriurgo dello spedale maggiore di milano. Opuscoli Scelti Sulle Scienze e Sulle Arti 5: 87-95.
34. Canfield, L. M., M. T. Clandinin et al. (2003). Multinational study of major breast milk carotenoids of healthy mothers. Eur. J. Nutr. 42(3): 133-141.
35. Cantrell, A., D. J. McGarvey et al. (2003). Singlet oxygen quenching by dietary carotenoids in a model membrane environment. Arch. Biochem. Biophys. 412(1): 47-54.
36. Cardinault, N., J. Gorrand et al. (2003). Short-term supplementation with lutein affects biomarkers of lutein status similarly in young and elderly subjects. Exp. Gerontol. 38(5): 573-582.
37. Cho, E., J. M. Seddon et al. (2004). Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch. Ophthalmol. 122(6): 883-892.
38. Cilotti, P. (1963). The action of thioctic acid and helenien on visual acuity in reduced lighting in normal subjects (Italian). Ann. Ottalmol. Clin. Ocul. 89: 1000-1004.
39. Coleman, H. and E. Chew (2007). Nutritional supplementation in age-related macular degeneration. Curr. Opin. Ophthalmol. 18(3): 220-223.
40. Craft, N. E., T. B. Haitema et al. (2004). Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J. Nutr. Health Aging 8(3): 156-162.
41. Cuccagna, F. (1956). Effect of helenien on retinal adaptation in myopia and retinitis pigmentosa (Italian). Arch. Ottal. 60: 311-321.
42. Cüppers, C. and E. Wagner (1950). Pharmacological effect on retinal function; normal dark adaptation (German). Klin Monatsblätter Augenheilkd 117(1): 59-69.
43. Dagnelie, G., I. S. Zorge et al. (2000). Lutein improves visual function in some patients with retinal degeneration: A pilot study via the Internet. Optometry 71(3): 147-164.
44. Daicker, B., K. Schiedt et al. (1987). Canthaxanthin retinopathy-An investigation by light and electron microscopy and physicochemical analysis. Graefe’s Arch. Clin. Exp. Ophthalmol. 225(3): 189-197.
45. De Ferreira, C. and C. Da Maia (1956). Effect of adaptinol in primary pigmentary retinosis (Portugese). Gaz. Med. Port. 9(5): 579-581.
46. de Jong, P. T. (2006). Age-related macular degeneration. N. Engl. J. Med. 355(4): 1474-1485.
47. Delcourt, C., I. Carriere et al. (2006). Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: The POLA study. Invest. Ophthalmol. Vis. Sci. 47(6): 2329-2335.
48. deVries, H., R. Jielof et al. (1953). Properties of the eye with respect to polarized light. Physica 19: 419-432.
49. Dillon, J., L. Zheng et al. (2004). Transmission of light to the aging human retina: possible implications for age related macular degeneration. Exp. Eye Res. 79(6): 753-759.
50. Dowling, J. E. (1987). The Retina, an Approachable Part of the Brain. The Belknap Press of Harvard University Press, Cambridge, MA and London.
51. Duncan, J. L., T. S. Aleman et al. (2002). Macular pigment and lutein supplementation in choroideremia. Exp. Eye Res. 74(3): 371-381.
52. During, A., S. Doraiswamy et al. (2008). Xanthophylls are preferentially taken up compared to beta-carotene by retinal cells via a scavenger receptor BI-dependent mechanism. J. Lipid Res. 49: 1715-1724.
53. EDCC Study Group (1993). Antioxidant status and neovascular age-related macular degeneration. Arch. Ophthalmol. 111: 104-109.
54. Engles, M., B. Wooten et al. (2007). Macular pigment: A test of the acuity hypothesis. Invest. Ophthalmol. Vis. Sci. 48(6): 2922-2931.
55. Falsini, B., M. Piccardi et al. (2003). Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: A pilot study including electrophysiologic assessment. Ophthalmology 110(1): 51-60.
56. Fincham, E. F. (1936). The photography of the human eye. J. Photogr. 76: 268-274.
57. Fletcher, A. E., G. C. Bentham et al. (2008). Sunlight exposure, antioxidants, and age-related macular degeneration. Arch. Ophthalmol. 126(10): 1396-1403.
58. Flood, V., W. Smith et al. (2002). Dietary antioxidant intake and incidence of early age-related maculopathy: The blue mountains eye study. Ophthalmology 109(12): 2272-2278.
59. Frank, H. A. and R. J. Cogdell (1996). Carotenoids in photosynthesis. Photochem. Photobiol. 63(3): 257-264.
60. Friedman, D. S., B. J. O’Colmain et al. (2004). Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4): 564-572.
61. Gabrielska, J. and W. I. Gruszecki (1996). Zeaxanthin (dihydroxy-beta-carotene) but not beta-carotene rigidifies lipid membranes: A 1H-NMR study of carotenoid-egg phosphatidylcholine liposomes. Biochim. Biophys. Acta 1285(2): 167-174.
62. Gale, C. R., N. F. Hall et al. (2003). Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 44(6): 2461-2465.
63. Garnett, K. M., L. H. Guerra et al. (2002). Serum and macular pigment responses to supplementation with lutein or zeaxanthin. ARVO 2002: Abstracts Volume #1, Program #2820.
64. Gass, J. D. (1997). Stereoscopic Atlas of Macular Diseases Diagnosis and Treatment. Vol. 1, Mosby-Year Book Inc., p. 3.
65. Gass, J. D. M. (1999). Müller cell cone, an overlooked part of the anatomy of the fovea centralis. Arch. Ophthalmol. 117: 821-823.
66. Goralczyk, R., F. M. Barker et al. (2000). Dose dependency of canthaxanthin crystals in monkey retina and spatial distribution of its metabolites. Invest. Ophthalmol. Vis. Sci. 41(6): 1513-1522.
67. Goralczyk, R., F. M. Barker et al. (2002). Ocular safety of lutein and zeaxanthin in a long-term study in cynomolgous monkeys. ARVO 2002 Abstracts Volume #1, Program #2546.
68. Hammond, B. R. and J. E. Frick (2007). Nutritional protection of the developing retina. Hong Kong Pract. 29: 1-8.
69. Hammond, B. R., K. Fuld et al. (1995). Macular pigment density in monozygotic twins. Invest. Ophthalmol. Vis. Sci. 36(12): 2531-2541.
70. Hammond, B. R., E. J. Johnson et al. (1997). Dietary modification of human macular pigment density. Invest. Ophthalmol. Vis. Sci. 38(9): 1795-801.
71. Hammond, B. R., B. R. Wooten et al. (2001). Carotenoids in the retina and lens: Possible acute and chronic effects on human visual performance. Arch. Biochem. Biophys. 385(1): 41-46.
72. Hammond, B. R. and B. R. Wooten (2005). CFF thresholds: Relation to macular pigment optical density. Ophthal. Physiol. Opt. 25(4): 315-319.
73. Handelman, G. J., Z. D. Nightingale et al. (1999). Lutein and zeaxanthin concentrations in plasma after dietary supplementation with egg yolk. Am. J. Clin. Nutr. 70: 247-251.
74. Harikumar, K. B., C. V. Nimita et al. (2008). Toxicity profile of lutein and lutein ester isolated from marigold flowers (Tagetes erecta). Int. J. Toxicol. 27(1): 1-9.
75. Harnois, C., J. Samson et al. (1989). Canthaxanthin retinopathy. Anatomic and functional reversibility. Arch. Ophthalmol. 107(4): 538-540.
76. Hartmann, D., P. A. Thürmann et al. (2004). Plasma kinetics of zeaxanthin and 3′-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. Am. J. Clin. Nutr. 79(3): 410-417.
77. Hayano, S., Y. Koide et al. (1959). Actions of adaptinol observed from the blood lutein pattern (Japanese). J. Clin. Ophthalmol. 13(6): 931-937.
78. Holm, E. (1922). Das gelbe maculapigment und seine optische bedeutung. Graefe’s Arch. Clin. Exp. Ophthalmol. 108(1-2): 1-85.
79. Home, E. (1798). An account of the orifice in the retina of the human eye, discovered by Professor Soemmering. Philos. Trans. R. Soc. London. Pt 2: 332-345.
80. Huang, K. C. (1993). The Pharmacology of Chinese Herbs. CRC Press, New York, pp. 221-215.
81. Huang, L. L., H. R. Coleman et al. (2008). Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years and older, with or without age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49(9): 3864-3869.
82. Inbaraj, B. S., H. Lu et al. (2008). Determination of carotenoids and their esters in fruits of Lycium barbarum Linnaeus by HPLC-DAD-APCI-MS. J. Pharm. Biomed. Anal. 47(4-5): 812-818.
83. Izumi-Nagai, K., N. Nagai et al. (2007). Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arterioscler. Thromb. Vasc. Biol., Oct. 11 [Epub ahead of print].
84. Jackson, J. G. and J. P. Zimmer (2007). Lutein and zeaxanthin in human milk independently and significantly differ among women from Japan, Mexico, and the United Kingdom. Nutr. Res. 27(8): 449-453.
85. Johnson, E. J., H. Y. Chung et al. (2008a). The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. Am. J. Clin. Nutr. 87(5): 1521-1529.
86. Johnson, E. J., K. A. McDonald et al. (2008b). Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr. Neurosci. 11(2): 75-83.
87. Johnson, E. J., M. Neuringer et al. (2005). Nutritional manipulation of primate retinas. III. Effects of lutein or zeaxanthin supplementation on adipose and retina of xanthophyll-free monkeys. Invest. Ophthalmol. Vis. Sci. 46(2): 692-702.
88. Johnson, E. J. and E. Norkus (1995). Contribution of beta-carotene from beta-carotene enriched formulas to individual and total serum carotenoids in term infants. FASEB J. 9(4 Pt 3): 1869.
89. Kant, A. K. and B. I. Graubard (2007). Ethnicity is an independent correlate of biomarkers of micronutrient intake and status in American adults. J. Nutr. 137(11): 2456-2463.
90. Khachik, F., G. R. Beecher et al. (1995). Lutein, lycopene, and their oxidative metabolites in chemoprevention of cancer. J. Cell. Biochem. Suppl. 22: 236-246.
91. Khachik, F., P. S. Bernstein et al. (1997a). Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest. Ophthalmol. Vis. Sci. 38(9): 1802-1811.
92. Khachik, F., E. London et al. (2006). Chronic ingestion of (3R,3′R,6′R)-lutein and (3R,3′R)-zeaxanthin in the female rhesus macaque. Invest. Ophthalmol. Vis. Sci. 47(12): 5476-5486.
93. Khachik, F., C. J. Spangler et al. (1997b). Identification, quantification, and relative concentrations of carotenoids and their metabolites in human milk and serum. Anal. Chem. 69: 1873-1881.
94. Kim, S. R., K. Nakanishi et al. (2006). Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. Exp. Eye Res. 82(5): 828-839.
95. Kirschfeld, K. (1982). Carotenoid pigments: Their possible role in protecting against photooxidation in eyes and photoreceptor cells. Proc. R. Soc. Lond. B Biol. Sci. 216(1202): 71-85.
96. Klaes, H. and H. Riegel (1951). Effect of adaptinol on dark adaptation of the human eye (German). Medizinische Monatsschrift 5(5): 334-337.
97. Koepcke, W., F. M. Barker et al. (1995). Canthaxanthin deposition in the retina: A biostatistical evaluation of 411 patients. J. Toxicol. Cutaneous Ocular Toxicol. 14(2): 89-104.
98. Koushik, A., D. J. Hunter et al. (2006). Intake of the major carotenoids and the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies. Int. J. Cancer 119(9): 2148-2154.
99. Kowluru, R. A., B. Menon et al. (2008). Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rats. Invest. Ophthalmol. Vis. Sci. 49(4): 1645-1651.
100. Krinsky, N. I. (2002). Possible biologic mechanisms for a protective role of xanthophylls. J. Nutr. 132(3): 540S-542S.
101. Krinsky, N. I. and S. M. Deneke (1982). Interaction of oxygen and oxy-radicals with carotenoids. J. Natl. Cancer Inst. 69(1): 205-210.
102. Krinsky, N. I., J. T. Landrum et al. (2003). Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu. Rev. Nutr. 23: 171-201.
103. Kuhn, R. and A. Winterstein (1930). About the occurrence of lutein in the plant kingdom (German). Naturwissenschaften 18: 754.
104. Kvansakul, J., M. Rodriguez-Carmona et al. (2006). Supplementation with the carotenoids lutein and zeaxanthin improves human visual performance. Ophthal. Physiol. Opt. 26(4): 362-371.
105. Landrum, J. T., R. A. Bone et al. (1997). A one year study of the macular pigment: The effect of 140 days of a lutein supplement. Exp. Eye Res. 65(1): 57-62.
106. Landrum, J. T., R. A. Bone et al. (1999a). Carotenoids in the human retina. Pure Appl. Chem. 71(12): 2237-2244.
107. Landrum, J. T., R. A. Bone et al. (1999b). Analysis of zeaxanthin distribution within individual human retinas. Methods Enzymol. 299: 457-467.
108. Leung, I. Y., M. M. Sandstrom et al. (2004). Nutritional manipulation of primate retinas, II: Effects of age, n-3 fatty acids, lutein, and zeaxanthin on retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 45(9): 3244-3256.
109. Leung, I. Y. F., M. O. M. Tso et al. (2001). Absorption of zeaxanthin in human subjects after ingestion of fructus lycii (gou qi zi). Invest. Ophthalmol. Vis. Sci. 42(4): S359, Program #1942.
110. Leyon, H., A. M. Ros et al. (1990). Reversibility of canthaxanthin deposits within the retina. Acta Ophthalmol (Copenh) 68(5): 607-611.
111. Liew, S. H., C. E. Gilbert et al. (2005). Heritability of macular pigment: A twin study. Invest. Ophthalmol. Vis. Sci. 46(12): 4430-4436.
112. Liew, S. H., C. E. Gilbert et al. (2006). Central retinal thickness is positively correlated with macular pigment optical density. Exp. Eye Res. 82(5): 915-920.
113. Lim, B. P., A. Nagao et al. (1992). Anti-oxidant activity of xanthophylls on peroxyl radical-mediated phospholipid peroxidation. Biochim. Biophys. Acta 1126: 178-184.
114. Loane, E., J. M. Nolan et al. (2008). Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular degeneration. Surv. Ophthalmol. 53(1): 68-81.
115. Loughman, J., P. Davison et al. (2007). Impact of macular pigment on visual performance. Optician 234(6116): 23-28.
116. Malinow, M. R., L. Feeney-Burns et al. (1980). Diet-related macular anomalies in monkeys. Invest. Ophthalmol. Vis. Sci. 19(8): 857-863.
117. Mares, J. A., T. L. LaRowe et al. (2006). Predictors of optical density of lutein and zeaxanthin in retinas of older women in the carotenoids in age-related eye disease study, an ancillary study of the women’s health initiative. Am. J. Clin. Nutr. 84(5): 1107-1122.
118. Marx, J. (2006). Genetics-A clearer view of macular degeneration. Science 311(5768): 1704-1705.
119. McNulty, H., R. F. Jacob et al. (2008). Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am. J. Cardiol. 101(10A): 20D-29D.
120. Moeller, S. M., P. F. Jacques et al. (2000). The potential role of dietary xanthophylls in cataract and age-related macular degeneration. J. Am. Coll. Nutr. 19(5 Suppl): 522S-527S.
121. Monje, M. (1948). On the effect of helenien on the darkness adjustment of humans with normal night vision (German). von Graefe’s Arch. Ophthalmol. 148: 679-705.
122. Mosci, L. (1956). Effect of heleniene (adaptinol) on sensitivity to light in man, experimental study (Italian). Ann. Ottalmol. Clin. Ocul. 82(5): 237-254.
123. Mueller-Limmroth, W., D. Berges et al. (1958). The effects of helenien and vitamin A on the primary visual processes. I. An electroretinographic study on the problem of the sites of helenien and vitamin A actions (German). Z. Biol. 110(5-6): 457-475.
124. Mueller-Limmroth, W. and J. Kueper (1961a). On the effect of adaptinol on the electroretinogram in tapetoretinal degenerations (German). Klin Monatsblätter Augenheilkd 138: 37-41.
125. Mueller-Limmroth, W. and B. Schmidt (1961b). The human ERG after glare in the course of early dark adaptation and its modification by adaptinol (German). Med. Welt 27: 1413-1421.
126. Nayak, L., M. K. Raval et al. (2001). Photoprotection of green leaves by zeaxanthin, a two-channel process. Curr. Sci. 81(9): 1165-1166.
127. Neuringer, M., M. M. Sandstrom et al. (2004). Nutritional manipulation of primate retinas, I: Effects of lutein or zeaxanthin supplements on serum and macular pigment in xanthophyll-free rhesus monkeys. Invest. Ophthalmol. Vis. Sci. 45(9): 3234-3243.
128. Nolan, J. M., J. Stack et al. (2006). Monthly consistency of macular pigment optical density and serum concentrations of lutein and zeaxanthin. Curr. Eye Res. 31(2): 199-213.
129. Nolan, J. M., J. Stack et al. (2007a). The relationships between macular pigment optical density and its constituent carotenoids in diet and serum. Invest. Ophthalmol. Vis. Sci. 48(2): 571-582.
130. Nolan, J. M., J. Stack et al. (2007b). Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Exp. Eye Res. 84(1): 61-74.
131. Nordenson, J. W. (1958). Neue argumente zur frage der makulafarbe. Graefe’s Arch. Clin. Exp. Ophthalmol. 160: 43-46.
132. Nussbaum, J. J., R. C. Pruett et al. (1981). Historic perspectives. Macular yellow pigment. The first 200 years. Retina 1(4): 296-310.
133. Obana, A., T. Hiramitsu et al. (2008). Macular carotenoid levels of normal subjects and age-related maculopathy patients in a Japanese population. Ophthalmology 115(1): 147-157.
134. O’Connell, E., K. Neelam et al. (2006). Macular carotenoids and age-related maculopathy. Ann. Acad. Med. Singapore 35(11): 821-830, Nov.
135. Oka, S. (1955). Experience with adaptinol (Bayer) in night blindness (Japanese). Ophthalmol. Japonica Folia 6(4): 156-160.
136. Olmedilla, B., F. Granado et al. (2001). Lutein in patients with cataracts and age-related macular degeneration: a long term supplementation study. J. Sci. Food Agric. 81(9): 904-909.
137. Parisi, V., M. Tedeschi et al. (2008). Carotenoids and antioxidants in age-related maculopathy Italian study: Multifocal electroretinogram modifications after 1 year. Ophthalmology 115(2): 324-333.
138. Pfeifer, H. (1957). Experiments on the effect of helenien on normal and reduced dark-adaptation (German). von Graefe’s Arch. Ophthalmol. 159(3): 311-322.
139. Rapp, L. M., S. S. Maple et al. (2000). Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Invest. Ophthalmol. Vis. Sci. 41(5): 1200-1209.
140. Reading, V. M. and R. A. Weale (1974). Macular pigment and chromatic aberration. J. Opt. Soc. Am. 64(2): 231-234.
141. Renzi, L. M., B. R. Hammond et al. (2008a). The effects of macular pigment on temporal vision. ARVO 2008: Abstract Book on CDROM: Program #4958.
142. Renzi, L. M., A. Iannaccone et al. (2008b). Relationships among macular pigment optical density (MPOD), serum lutein (L), zeaxanthin (Z), and n3 fatty acids (FAs). ARVO 2008: Abstract Book on CDROM: Program #2123.
143. Renzi, L. M. and E. J. Johnson (2007). Lutein and age-related ocular disorders in the older adult: A review. J. Nutr. Elder 26(3-4): 139-157.
144. Richer, S. (1999). Part II: ARMD-pilot (case series) environmental intervention data. J. Am. Optom. Assoc. 70(1): 24-36.
145. Richer, S., W. Stiles et al. (2004). Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: The veterans LAST study (lutein antioxidant supplementation trial). Optometry 75(4): 216-229.
146. Schalch, W. (1992). Carotenoids in the retina-A review of their possible role in preventing or limiting damage caused by light and oxygen. EXS (Experientia Suppl. Ser.) 62: 280-298.
147. Schalch, W. and F. M. Barker (2005). Ocular and general safety of supplementation with zeaxanthin and lutein; plasma exposure levels of carotenoids and 3´-dehydro-lutein—Results of the LUXEA study. ARVO 2005: Abstract Book on CDROM: Program #1765.
148. Schalch, W., W. Cohn et al. (2007). Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin-the LUXEA (lutein xanthophyll eye accumulation) study. Arch. Biochem. Biophys. 458(2): 128-135.
149. Schmitt, G., D. Berges et al. (1959). The effects of helenien and vitamin A on the primary sight process. II. Tissue respiration of the isolated retina under the influence of helenien and vitamin A (German). Z. Biol. 111: 213-219.
150. Schultze, M. (1866). Ueber den gelben fleck der retina, seinen einfluss auf normales sehen und auf farbenblindheit. Bonn, Verlag von Max Cohen & Sohn Vortrag gehalten in der Sitzung der Medicinischen Section der Niederrheinischen Gesellschaft für Natur-und Heilkunde zu Bonn am 9. Mai 1866: 1-16.
151. Schupp, C., E. Olano-Martin et al. (2004). Lutein, zeaxanthin, macular pigment, and visual function in adult cystic fibrosis patients. Am. J. Clin. Nutr. 79(6): 1045-1052.
152. Schwalbe, G. (1874). Microscopische Anatomie des Sehnerven, der Netzhaut und des Glaskörpers. Leipzig, Engelmann, Germany.
153. Schweitzer, D., G. E. Lang et al. (2000). Age-related maculopathy. Comparative studies of patients, their children and healthy controls (German). Ophthalmology 97(2): 84-90.
154. Schweitzer, D., G. E. Lang et al. (2002). Objective determination of the optical density of xanthophyll after supplementation with lutein (original German title: Objektive bestimmung der optischen dichte von xanthophyll nach supplementation von lutein). Ophthalmology 99: 270-275.
155. Seddon, J. M., U. A. Ajani et al. (1994). Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye disease case-control study group. JAMA 272(18): 1413-1420.
156. Seddon, J. M. and C. H. Hennekens (1994). Vitamins, minerals, and macular degeneration, promising but unproven hypotheses. Arch. Ophthalmol. 112: 176-179.
157. Shao, A. and J. N. Hathcock (2006). Risk assessment for the carotenoids lutein and lycopene. Regul. Toxicol. Pharmacol. 45(3): 289-298.
158. Sires, B. S., J. C. Saari et al. (2001). The color difference in orbital fat. Arch. Ophthalmol. 119(6): 868-871.
159. Snellen, E. L., A. L. Verbeek et al. (2002). Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol. Scand. 80(4): 368-371.
160. Snodderly, D. M., P. K. Brown et al. (1984). The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest. Ophthalmol. Vis. Sci. 25(6): 660-673.
161. Soemmering, S. T. (1799). De foramine centrali limbo luteo cincto retinae humanae (Latin). Commentationes Societatis Regiae Scientiarum Göttingensis 13: 3-13.
162. Sole, P., D. Rigal et al. (1984). Effects of cyaninoside chloride and heleniene on mesopic and scotopic vision in myopia and night blindness (French). J. Fr. Ophthalmol. 7(1): 35-39.
163. Sparrow, J. R. and M. Boulton (2005). RPE lipofuscin and its role in retinal pathobiology. Review. Exp. Eye Res. 80(5): 595.
164. Stringham, J. M., K. Fuld et al. (2003). Action spectrum for photophobia. J. Opt. Soc. Am. A Opt. Image Sci. Vis. 20(10): 1852-1858.
165. Stringham, J. M. and B. R. Hammond (2007). The glare hypothesis of macular pigment function. Optom. Vis. Sci. 84(9): 859-864.
166. Stringham, J. M. and B. R. Hammond (2008). Macular pigment and visual performance under glare conditions. Optom. Vis. Sci. 85(2): 82-88.
167. Sun, H. and J. Nathans (2001). The challenge of macular degeneration. Sci. Am. (Oct. Issue): 69-75.
168. Tarpo, E. and V. Cucu (1961). The blossoms of the genus Tagetes as the raw material for the production of helenien (German). Pharmazie 16: 486-488.
169. Thomson, L. R., Y. Toyoda et al. (2002). Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. Invest. Ophthalmol. Vis. Sci. 43(11): 3538-3549.
170. Thürmann, P. A., W. Schalch et al. (2005). Plasma kinetics of lutein, zeaxanthin, and 3′-dehydro-lutein after multiple oral doses of a lutein supplement. Am. J. Clin. Nutr. 82(1): 88-97.
171. Thurnham, D. I., A. Tremel et al. (2008). A supplementation study in human subjects with a combination of meso-zeaxanthin, (3R,3′R)-zeaxanthin and (3R,3′R,6′R)-lutein. Br. J. Nutr. 100(6): 1307-1314.
172. Trieschmann, M., S. Beatty et al. (2007). Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: The LUNA study. Exp. Eye Res. 84(4): 718-728.
173. Trumbo, P. R. and K. C. Ellwood (2006). Lutein and zeaxanthin intakes and risk of age-related macular degeneration and cataracts: An evaluation using the Food and Drug Administration’s evidence-based review system for health claims. Am. J. Clin. Nutr. 84(5): 971-974.
174. van den Langenberg, G. M., J. A. Mares-Perlman et al. (1998). Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the beaver dam eye study. Am. J. Epidemiol. 148(2): 204-214.
175. von Studnitz, G. (1952). Die Steigerung der Dunkeladaptation durch Adaptinol [Increase of dark adaptation by adaptinol] (German). Klin Monatsblätter Augenheilkd 120: 632-636.
176. von Studnitz, G. and H. K. Loevenich (1947). About the increase in human darkness adaptation by carotenoids (German). Klin Monatsblätter Augenheilkd 111: 193-210.
177. Wald, G., W. R. Carroll et al. (1941). The human excretion of carotenoids and vitamin A. Science 94(2430): 95-96.
178. Wald, G. L. (1945). Human vision and the spectrum. Nature (London) 101: 653-658.
179. Walls, G. L. and H. D. Judd (1933). The intra-ocular colour-filters of vertebrates. Br. J. Ophthalmol. 17: 641-675, 705-725.
180. Weale, R. A. (2007). Guest editorial: Notes on the macular pigment. Ophthal. Physiol. Opt. 27(1): 1-10.
181. Weiser, H. and A. W. Kormann (1993). Provitamin A activities and physiological functions of carotenoids in animals. Ann. N.Y. Acad. Sci. 691: 213-215.
182. Wenzel, A. J., K. Fuld et al. (2006). Macular pigment optical density and photophobia light threshold. Vis. Res. 46(28): 4615-4622.
183. Wenzel, A. J., J. P. Sheehan et al. (2007). Macular pigment optical density at four retinal loci during 120 days of lutein supplementation. Ophthal. Physiol. Opt. 27(4): 329-335.
184. Whitehead, A. J., J. A. Mares et al. (2006). Macular pigment: A review of current knowledge. Arch. Ophthalmol. 124(7): 1038-1045.
185. Whittaker, D., R. Steen et al. (1993). Light scatter in the normal young, elderly, and cataractous eye demonstrates little wavelength dependency. Optom. Vis. Sci. 70: 963-968.
186. Wolf-Schnurrbusch, U. E. K., N. Röösli et al. (2007). Ethnic differences in macular pigment density and distribution. Invest. Ophthalmol. Vis. Sci. 48(8): 3783-3787.
187. Wooten, B. R. and B. R. Hammond (2002). Macular pigment: Influences on visual acuity and visibility. Prog. Retin. Eye Res. 21(2): 225-240.
188. Wuestenberg, W. (1951). The effect of adaptinol on normal dark adaptation (German). Klin Monatsblätter Augenheilkd 119(5): 524-528.
189. Yakovleva, M. A., I. G. Panova et al. (2007). Identification of carotenoids in the vitreous body of the prenatal human eye. Ontogenez 38(5): 380-385.
190. Yang, Z., C. Stratton et al. (2008). Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N. Engl. J. Med., Aug. 27 [Epub ahead of print] Links.
191. Yeum, K. J., F. M. Shang et al. (1999). Fat-soluble nutrient concentrations in different layers of human cataractous lens. Curr. Eye Res. 19(6): 502-505.
192. Yolton, D., B. DeRuyter et al. (2002). Failure of oral supplement containing lutein to change macular pigment density. Optom. Vis. Sci. 79(12): 104.
193. Zimmer, J. P. and B. R. Hammond (2007). Possible influences of lutein and zeaxanthin on the developing retina. Clin. Ophthalmol. 1(1): 25-35.